* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
London Stock Exchange: Main Market and AIM
AIREA 27.00p £10.75m (AIEA.L)
The UK design-led specialist flooring Company supplying both the UK and international markets announced a trading update for the six months ended 30 June 2026. Group sales for the Period were 10.2% ahead of the prior year at £10.81m (H1 2025: £9.81m), including volume growth of 7.4%. Group operating profit for the Period was ahead of the prior year and the Board expects the strong momentum to continue through the remainder of the year and remains confident in the Group's long-term prospects and its ability to deliver sustainable long-term value for shareholders.
Eleco 128.00p £97.05m (ELCO.L)
The specialist software provider for the built environment provided a trading update for the six months ended 30 June 2026 based on unaudited management accounts for the Period. Annualised Recurring Revenue at 30 June 2026 increased 16% to c.£35.5m (£30.7m at 30 June 2025), reflecting a further new record for the Group's ARR. Headline total revenue for the period increased by 8% to c.£19.9m (H1 2025: £18.4m); and in constant currency terms approximately £19.6m. Cash at 30 June 2026 was £15.4m (at 30 June 2025: £12.2m; at 31 December 2025: £16.3m) and the Group remains free of debt.
The Interim Results will be reported in full in September.
Fonix 172.0p £158.64m (FNX.L)
The mobile payments and messaging provider provided an update on trading for the year ended 30 June 2026. Gross profit and adjusted EBITDA in FY26 have grown slightly ahead of market expectations, with gross profit for the Year increasing by 12.9% to £21.0m (FY25: £18.6m). Total payment volume increased by 8.0% to £303.3m (FY25: £280.9m). Fonix intends to pay an increased final dividend, in line with the Group's progressive dividend policy to pay out at least 75% of adjusted earnings per share. In May 2026, the Group also completed a £2.0m on-market share buyback, underlining the Board's confidence in the Group's strong cash generation alongside its growing ordinary dividend. The Board reports the Group is building strong momentum for future growth and looks to FY27 with real confidence.
hVIVO 6.75p £46.47m (HVO.L)
The clinical development partner provided an unaudited trading update for the six months ended 30 June 2026. Revenue of £16.3m (H1 2025: £24.2m) with full year 2026 revenue to be heavily weighted to the second half. The orderbook has more than doubled to £65m, compared with £30m at the start of the year. Adjusted EBITDA for H1 2026 is expected to be negative mid-single digit (H1 2025: adjusted EBITDA of £3.0m), with positive adjusted EBITDA expected in H2 2026. Cash of £13m as at 30 June 2026 (31 December 2025: £14.3m). The Company expects 2026 full-year revenue to be broadly in line with expectations of high single-digit revenue growth.
LPA Group 83.50p £9.80m (LPA.L)
The innovation-led engineering Company that designs and manufactures electronic and electromechanical components and systems reports a new distribution agreement with Boeing Distribution. Boeing will leverage its established global network to distribute LPA Red Box Aviation's product portfolio. An initial stocking order is for around £0.5m. The agreement is a significant milestone on the strategy to diversify away from the rail sector and is the start of a strategic relationship with Boeing Distribution to serve the general aviation market.
Oriole Resources 0.38p £17.38m (ORR.L)
The gold exploration and development Company focused on Central and West Africa published an updated JORC Mineral Resource Estimate (MRE) for the MB01-S deposit at its 50% owned Mbe orogenic gold project in Cameroon. Together with the MRE for the neighbouring MB01-N deposit, which was published on 13 April 2026, the total JORC Inferred Mineral Resource at the Project is now 1.66m oz contained gold (Au) with a mean grade of 1.02g/t. The Company believes that the Project has multi-million-ounce potential.
Scancell Holdings 10.75p £132.32m (SCLP.L)
The developer of active immunotherapies to treat cancer announced a merger and financing today.
Scancell and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) today announced an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the Transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol SCLT.
Alongside the Merger, Scancell expects to secure up to $89m of financing through a combination of equity and debt. It has secured commitments from new and existing shareholders for a Private Placement of $39.1m (c.£29.2m) and intends to launch today a UK Placing to raise approximately $12.0m (c.£9.0m) and a Retail Offer to raise up to $3.0m (c.£2.3m). The UK Placing is not conditional on the US Listing Transactions.
The MISSION Group 19.0p £14.3m (TMG.L)
The collective of Creative, Sports and MarTech Agencies provided a trading update for the six months ended 30 June 2026 (H1 2026). The Group's H1 2026 performance was in line with the Board's expectations, with improved headline operating profit before adjustments expected to be up 10% at £2.4m (30 June 2025: £2.2m) and H1 revenue expected to be £32.5m (30 June 2025: £34.1m). Headline profit before tax is expected to be 27% higher at £1.4m (30 June 2025: £1.1m). Net bank debt was £11.0m on 30 June 2026 (£13.7m on 30 June 2025, and £9.0m on 31 December 2025). While market conditions remain uncertain, the Board remains confident in delivering profitable growth across all business segments, with the Group on track to meet full year market expectations.
The Works 76.60p £49.38m (WRKS.L)
The specialist retailer of affordable, screen-free activities announced its Preliminary Results for the 52 weeks ended 3 May 2026. Total revenue increased 3.1% to £260m (FY25: £252m), adjusted profit before tax (from continuing operations) increased by 44% year-on-year to £7.2m (FY25: £5.0m) and net cash of £3.6m (FY25: £4.1m). The Board is encouraged by the Group's strong trading performance in FY27 to date, while remaining mindful of the continuing macroeconomic uncertainty. With the key back-to-school and Christmas trading periods still ahead, the Board is maintaining its recently upgraded FY27 guidance for pre-IFRS 16Adjusted EBITDA of £15.0m.
Aquis Market
ProBiotix Health 7.50p £11.86m (AQSE: PBX) The life sciences business developing probiotics to support cardiometabolic health announced a new partnership agreement with Belgium based Nutrisan. ProBiotix has secured a commercial cooperation with Nutrisan to supply its patented probiotic strain LP for a new standalone product launched under the Nutrisan PRO brand, targeted at pharmacists and healthcare professionals across Belgium. Nutrisan is a leading Belgian nutraceutical company, specialising in the development, production and distribution of high-quality, natural food supplements since 1998.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
Bravura Solutions (ASX: BVS) the global provider of enterprise software for the wealth management and funds administration industries has announced its intention to dual list on AIM. Bravura is currently listed on the Australian Securities Exchange (ASX) and Admission to AIM is being sought via the AIM Designated Market Route. No capital to be raised on Admission with a market cap on Admission of circa £500m. Expected Admission date is 28 July.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
